Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s

About 20,000 people are taking Eli Lilly’s obesity pill Foundayo after its first 20 days on the market, according to the company’s CEO David Ricks. This points to a markedly slower launch of the drug ...